Finn Myhren

USPTO Granted Patents = 20 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 84(Granted Patents)

Location History:

Porsqrunn, NO (2004)
Porsgunn, NO (2013)
Porsgrunn, NO (2000 - 2016)
Oslo, NO (2018 - 2023)
Stamsund, NO (2021 - 2023)

Company Filing History:

8 out of 35

Aker Biomarine Antarctic As

Mount Sinai School of Medicine

patents

6. 1 out of 896

The United States Government As Represented by the Department of Veterans Affairs

patents

7. 1 out of 447

University of Alberta

where one patent can have more than one assignee

Years Active: 2000-2023

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11819509 - Lipid compositions (2023-11-21),

2. 11744864 - Method of treating eye diseases with krill oil (2023-09-05),

3. 11065267 - Lysophosphatidylcholine compositions (2021-07-20),

4. 11020438 - Phospholipid compositions and their preparation (2021-06-01),

5. 10960016 - Capsules containing high doses of krill phospholipids (2021-03-30),

6. 10864223 - Lipid compositions (2020-12-15),

7. 10806742 - Liquid phospholipid-containing compositions for the preparation of pharmaceuticals (2020-10-20),

8. 10456412 - Lipid extraction processes (2019-10-29),

9. 9867856 - Phospholipid compositions and their preparation (2018-01-16),

10. 9428540 - Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents (2016-08-30),

11. 8912162 - Parenteral formulations of elacytarabine derivatives (2014-12-16),

12. 8722041 - Anti-human equilibrative nucleoside transporter 1 (hENT1) antibodies and methods of use thereof (2014-05-13),

13. 8399420 - Azacytidine analogues and uses thereof (2013-03-19),

14. 8349834 - Dioxolane derivates for the treatment of cancer (2013-01-08),

15. 6762175 - Fatty acid derivatives (2004-07-13),

Title: Inventor Profile: Finn Myhren

Introduction

Finn Myhren is a distinguished inventor based in Porsgrunn, Norway, known for his innovative contributions to pharmaceutical formulations and cancer treatment. With an impressive portfolio of 11 patents, he has made significant strides in the field of medicinal chemistry, particularly through his work on glucocorticoid derivatives.

Latest Patents

Among his latest inventions are two noteworthy patents. The first is titled "Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents." This invention focuses on certain unsaturated fatty acid derivatives of therapeutically active glucocorticoids, offering potential treatment options for inflammatory and cancerous conditions through pharmaceutical formulations. The second patent, "Parenteral formulations of elacytarabine derivatives," pertains to parenteral formulations for long chain saturated and monounsaturated fatty acid derivatives of 1-β-D-arabinofuranosylcytosine (cytarabine). This invention emphasizes the preparation of effective doses for cancer treatment, enhancing patient compliance.

Career Highlights

Finn Myhren has had a notable career, working with reputable companies such as Norsk Hydro ASA and Clavis Pharma ASA. His expertise has been instrumental in advancing the development of innovative therapeutic solutions in the pharmaceutical industry.

Collaborations

Throughout his career, Finn has collaborated with various professionals, including colleagues Are Dalen and Marit Liland Sandvold. These partnerships have fostered a multidisciplinary approach to his research and development efforts, leading to successful innovations.

Conclusion

Finn Myhren stands out as a prolific inventor in the pharmaceutical field, with a focus on innovative solutions for cancer treatment and anti-inflammatory therapies. His patented inventions and collaborative spirit continue to influence the industry, making a lasting impact on healthcare and medicine.

This text is generated by artificial intelligence and may not be accurate.